Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2011-6-21
pubmed:abstractText
Staphylococcal enterotoxins A (SEA) and B (SEB) are classical models of superantigens (SAg), which induce potent T-cell-stimulating activity by forming complexes with MHC class II molecules on antigen-presenting cells. This large-scale activation of T-cells is accompanied by increased production of cytokines such as interferon-? (IFN-?). Additionally, as we previously reported, IFN-?-producing CD8(+) T cells act as "helper cells," supporting the ability of dendritic cells to produce interleukin-12 (IL-12)p70. Here, we show that DC pulsed with SAg promote the enhancement of anti-tumor immunity. Murine bone marrow-derived dendritic cells (DC) were pulsed with OVA(257-264) (SIINFEKL), which is an H-2Kb target epitope of EG7 [ovalbumin (OVA)-expressing EL4] cell lines, in the presence of SEA and SEB and were subcutaneously injected into naïve C57BL/6 mice. SAg plus OVA(257-264)-pulsed DC vaccine strongly enhanced peptide-specific CD8(+) T cells exhibiting OVA(257-264)-specific cytotoxic activity and IFN-? production, leading to the induction of protective immunity against EG7 tumors. Furthermore, cyclophosphamide (CY) added to SAg plus tumor-antigens (OVA(257-264), tumor lysate, or TRP-2) pulsed DC immunization markedly enhanced tumor-specific T-cell expansion and had a significant therapeutic effect against various tumors (EG7, 2LL, and B16). Superantigens are potential candidates for enhancing tumor immunity in DC vaccines.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1432-0851
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1029-38
pubmed:meshHeading
pubmed-meshheading:21519830-Animals, pubmed-meshheading:21519830-Antigen-Presenting Cells, pubmed-meshheading:21519830-Antineoplastic Agents, Alkylating, pubmed-meshheading:21519830-CD8-Positive T-Lymphocytes, pubmed-meshheading:21519830-Carcinoma, Lewis Lung, pubmed-meshheading:21519830-Cyclophosphamide, pubmed-meshheading:21519830-Cytokines, pubmed-meshheading:21519830-Dendritic Cells, pubmed-meshheading:21519830-Flow Cytometry, pubmed-meshheading:21519830-Histocompatibility Antigens Class II, pubmed-meshheading:21519830-Interferon-gamma, pubmed-meshheading:21519830-Interleukin-12, pubmed-meshheading:21519830-Lung Neoplasms, pubmed-meshheading:21519830-Lymphocyte Activation, pubmed-meshheading:21519830-Lymphoma, pubmed-meshheading:21519830-Male, pubmed-meshheading:21519830-Melanoma, Experimental, pubmed-meshheading:21519830-Mice, pubmed-meshheading:21519830-Mice, Inbred C57BL, pubmed-meshheading:21519830-Ovalbumin, pubmed-meshheading:21519830-Receptors, G-Protein-Coupled, pubmed-meshheading:21519830-Superantigens, pubmed-meshheading:21519830-Survival Rate, pubmed-meshheading:21519830-T-Lymphocytes, Cytotoxic, pubmed-meshheading:21519830-T-Lymphocytes, Helper-Inducer, pubmed-meshheading:21519830-Tumor Cells, Cultured, pubmed-meshheading:21519830-Vaccines, Subunit
pubmed:year
2011
pubmed:articleTitle
Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells.
pubmed:affiliation
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't